Mikhail Blagosklonny is a renowned Oncologist Professor at Roswell Park Cancer Institute. He has a Ph.D. in Experimental Medicine and Cardiology as well as a Master’s degree in Internal Medicine. Due to his excellent work in these fields, Mikhail was not only appointed as an Associate Professor of Medicine at New York Medical College but also a Senior Scientist in Ordway Research Institute. Blagosklonny is passionate about research work on therapies that protect normal body cells from targeted cancer treatment procedures and cancer-related tissue damages. He also has an interest in the process of aging and development of anti-aging drugs. Mikhail is known for his tangible contribution and advocating for the use of Rapamycin in order to increase human lifespan. Rapamycin is commonly known in pharmacy market as Rapamune or Sirolimus. It is a revolutionary cancer drug and is also used to prevent rejection of organ transplant.
The drug was first isolated from bacterium sample in Easter Island in 1972. It was originally used to treat a fungal infection until a research was conducted and showed that Rapamycin had incredible antiproliferative and immunosuppressive properties.Rapamycin has proven to be one of the best medicines due to its unique properties that make it outweigh other medications. For starters, compared to other immunosuppressive drugs, Rapamycin has low side effects and toxicity level on the kidney. It is recommended for people suffering from hemolytic-uremic syndrome after a kidney transplant. Besides, it reduces kidney re-infection and is less toxic to the kidney. Mostly, the drug is used to treat Lymphangioleiomyomatosis (LAM), coating coronary stent in addition to cancer. Studies showed that Rapamycin prevents the growth of tumor in areas such as the brain, kidney, heart, and other vital organs. As a result, it is also used to treat facial angiofibroma, Alzheimer’s disease, muscular dystrophy, systematic lupus erythematosus (SLE), and lengthening lifespan.
Mikhail Blagosklonny is aiming at finding a way to treating cancer that is cheaper and effective compared to the current expensive and torturing cancer treatment procedures. He is specifically focused on studying both cancer and aging. More interestingly, Mikhail hopes that his progressive work in medicine will be an inspiration to other people around the world to carry on with his research work in order to bring more transformation in cancer treatment. He believes that cancer treatment will be affordable to everyone and not a costly treatment only available for the rich. \Additionally, he hopes to discover a way in which cancerous cells will be eliminated without damaging the normal cells that assist the body to recover from prolonged effects of cancer treatment. He is still carrying on with his medical research and continues to contribute significantly in the field of Oncology. Mikhail Blagosklonny is not only an influential researcher but also an expert who inspires his peers and students with interest in expanding and continuing his research. The interesting medical work of Mikhail Blagosklonny has drawn a lot of attention within the field of medicine, and everyone hopes it will be a breakthrough to cancer patients.
Eric Lefkofsky does not enjoy starting new companies. The entrepreneur has taken many startups public while becoming wealthy and establishing his reputation as one of the great tech founders. However, Lefkofsky’s life changed when his wife was diagnosed with cancer. To help adjust to the shock of his wife’s diagnosis, Lefkofsky helped develop Tempus, which uses data to help with cancer treatments. Tempus uses machine learning to help understand a patient’s diagnosis. Tempus then creates a treatment plan to help fight the tumor. Lefkofsky feels that Tempus is a symbol of a technology shift within healthcare.
Lefkofsky is committed to using millions of dollars from his own finances to help Tempus, which Lefkofsky feels gives him an advantage over other competitors who constantly need financing. While Lefkofsky doesn’t really enjoy starting companies, Tempus was created because there was a problem that lacked a solution. As Lefkofsky went with his wife to Eric Lefkofsky treatments, he met with doctors and wondered why they didn’t use data that could help their decision making.
Tempus has formed numerous partnerships with different healthcare organizations, including The University of Michigan, Northwestern University, and The Mayo Clinic. Tempus looks at the patient’s clinical and molecular information, then sends the results to the doctors. Doctors are then able to analyze the mutations of the patient and what treatment options would be the most beneficial. While it will take time to determine Tempus’s real significance, the company has been endorsed by several top cancer clinics.
Lefkofsky is also a founding partner of Lightbank, a venture fund that invests in disruptive technologies. Lefkofsky has also helped found Groupon, Uptake Technologies, Echo Global Logistics, and InnerWorkings.
Lefkofsky established the Lefkofsky Family Foundation with his wife to help start initiatives that help people in different communities.
Lefkofsky earned his degree from The University of Michigan and received his Juris Doctor from The University of Michigan Law School.
Eric Lefkofsky is the co-founder and CEO of Tempus, a company focused on using genomic data in a clinical setting. The overall goal is to allow each new patient to benefit from the experiences of those who came before them. Physicians are able to use collected data to find the best strategies for future treatments.Tempus helps doctors personalize cancer treatment for their patients by collecting and analyzing data from clinical studies on other patient’s outcomes using similar strategies. They recently started working with Duke University School of Medicine on a new program to better treat brain cancer. Tempus will provide molecular sequencing and other data analysis for glioblastoma patients in the study at Duke.
Eric is also the co-founder of Lightbank, a venture capital fund that specializes in investing in disruptive technology. He currently serves as a managing director of Lightbank. The company helps young entrepreneurs make their ideas come to life. He is also the co-founder and Chairman of Groupon, a global e-commerce business. He is a co-founder of Uptake Technologies, a predictive analytics platform provider.Lefkofsky along with his wife Liz are co-chairs of the Lefkofsky Family Foundation. The foundation supports many organizations and initiatives within the communities they serve. He is a Trustee of Lurie Children’s Hospital in Chicago. He is also a supporter of The Art Institute of Chicago, World Business in Chicago, and The Museum of Science and Industry.
Eric is an adjunct professor at the University of Chicago. He is Chairman of the Board of Trustees at Steppenwolf Theatre Company. He wrote “Accelerated Disruption: Understanding the True Speed of Innovation.” He is a graduate of University of Michigan and received his law degree from the University of Michigan Law School.Eric Lefkofsky has had many successes in his life and has used his success to help others in need. He says that in business it’s critical to see what motivates other people, because this is what business motivation is all about. He believes that when we all start having more empathy for each other the world will become a much better place.